ORGANIZATION

Budget Juggling Dependent on Drug Price Cuts Unacceptable: Tokyo Pharma Chief

January 9, 2019
The pharma industry cannot tolerate the government’s over-dependence on drug price cuts in its annual budget formulations despite its pledge to balance cost retrenchments with efforts to spur innovation, Tatsuo Higuchi, president of the Pharmaceutical Manufacturers’ Association of Tokyo, stressed…

To read the full story

ORGANIZATION

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…